JUNTENDO UNIVERSITY

Suvorexant Shows Promise in Reducing Hyperactive Delirium in Older Adults: A Randomized Clinical Trial

- A clinical trial investigated suvorexant's efficacy in reducing delirium among older adults at high risk after hospitalization, a condition associated with increased morbidity and healthcare costs. - The study found a trend toward delirium reduction with suvorexant, though the overall difference was not statistically significant compared to placebo. - Post-hoc analysis revealed suvorexant may be more effective against hyperactive and mixed delirium subtypes, suggesting a potential benefit in managing agitation and impulsivity. - These findings indicate suvorexant could improve outcomes for older adults at risk of delirium, particularly those exhibiting hyperactive symptoms, potentially easing the burden on healthcare providers.